固有免疫与乙型肝炎病毒持续感染。
Innate immunity and HBV persistence.
机构信息
Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA.
Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA.
出版信息
Curr Opin Virol. 2021 Aug;49:13-20. doi: 10.1016/j.coviro.2021.04.003. Epub 2021 May 13.
Abstract
Hepatitis B virus (HBV) causes chronic infections that are associated with immune dysfunction. Though T cell impairment is perhaps the most prominent immune change contributing to viral persistence, HBV interaction with the innate immune system is also likely key, as the lack of effective innate immunity has functional consequences that promote chronic infection. In addition to an intrinsic ability to fight viral infections, the innate immune system also impacts T cell responses and other adaptive immune mechanisms critical for HBV control. Therefore, it is essential to understand the relationships between HBV and innate immunity, as these interactions may be useful immunotherapeutic targets to manage the infection.
摘要
乙型肝炎病毒 (HBV) 可引起慢性感染，与免疫功能障碍有关。虽然 T 细胞损伤可能是导致病毒持续存在的最显著的免疫改变，但 HBV 与先天免疫系统的相互作用也可能是关键，因为缺乏有效的先天免疫会产生促进慢性感染的功能后果。除了固有抵抗病毒感染的能力外，先天免疫系统还会影响 T 细胞反应和其他对 HBV 控制至关重要的适应性免疫机制。因此，了解 HBV 与先天免疫之间的关系至关重要，因为这些相互作用可能是管理感染的有用免疫治疗靶点。
相似文献
1
Innate immunity and HBV persistence.固有免疫与乙型肝炎病毒持续感染。
Curr Opin Virol. 2021 Aug;49:13-20. doi: 10.1016/j.coviro.2021.04.003. Epub 2021 May 13.
2
Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.Toll样受体通过启动抗病毒固有免疫反应和促进特异性适应性免疫反应对控制乙型肝炎病毒感染的作用。
Cell Mol Immunol. 2015 May;12(3):273-82. doi: 10.1038/cmi.2014.112. Epub 2014 Nov 24.
3
Adaptive immunity in HBV infection.HBV 感染中的适应性免疫。
J Hepatol. 2016 Apr;64(1 Suppl):S71-S83. doi: 10.1016/j.jhep.2016.01.026.
4
The role of innate immunity in the immunopathology and treatment of HBV infection.固有免疫在乙型肝炎病毒感染的免疫病理学和治疗中的作用。
J Hepatol. 2016 Apr;64(1 Suppl):S60-S70. doi: 10.1016/j.jhep.2016.01.028.
5
Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.迈向慢性乙型肝炎病毒感染的治愈性免疫调节策略
ACS Infect Dis. 2019 May 10;5(5):703-712. doi: 10.1021/acsinfecdis.8b00297. Epub 2019 Apr 3.
6
HBV and the immune response.HBV 与免疫应答。
Liver Int. 2015 Jan;35 Suppl 1:121-8. doi: 10.1111/liv.12749.
7
Innate and adaptive immune responses in hepatitis B virus infection.乙型肝炎病毒感染中的先天和适应性免疫反应。
Dig Dis. 2010;28(1):126-32. doi: 10.1159/000282075. Epub 2010 May 7.
8
Immunopathogenesis of chronic hepatitis B.慢性乙型肝炎的免疫发病机制
World J Gastroenterol. 2014 Oct 21;20(39):14156-71. doi: 10.3748/wjg.v20.i39.14156.
9
Reversal of hepatitis B virus-induced systemic immune tolerance by intrinsic innate immune stimulation.固有先天免疫刺激逆转乙型肝炎病毒诱导的全身免疫耐受。
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:132-7. doi: 10.1111/jgh.12034.
10
Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy.经基于干扰素的联合疗法治疗后，慢性乙型肝炎患者 T 细胞功能得到恢复。
J Hepatol. 2016 Mar;64(3):539-46. doi: 10.1016/j.jhep.2015.10.013. Epub 2015 Oct 24.
引用本文的文献
1
Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection.抗乙肝病毒治疗可部分恢复慢性乙肝病毒感染过程中固有免疫细胞和非常规T细胞的功能障碍。
Front Immunol. 2025 Jul 4;16:1611976. doi: 10.3389/fimmu.2025.1611976. eCollection 2025.
2
Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges.人类嗜T淋巴细胞病毒（HTLV）：流行病学、遗传学、发病机制及未来挑战
Viruses. 2025 May 1;17(5):664. doi: 10.3390/v17050664.
3
Contradictory Mechanisms of rheumatoid arthritis and hepatitis B virus infection activation.类风湿性关节炎与乙型肝炎病毒感染激活的矛盾机制。
Heliyon. 2024 Dec 26;11(1):e41444. doi: 10.1016/j.heliyon.2024.e41444. eCollection 2025 Jan 15.
4
Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies.病毒性肝炎：宿主免疫相互作用、发病机制及新治疗策略
Pathogens. 2024 Sep 5;13(9):766. doi: 10.3390/pathogens13090766.
5
Tripartite Motif-Containing Protein 65 (TRIM65) Inhibits Hepatitis B Virus Transcription.三结构域蛋白 65（TRIM65）抑制乙型肝炎病毒转录。
Viruses. 2024 May 31;16(6):890. doi: 10.3390/v16060890.
6
Recent advances in different interactions between toll-like receptors and hepatitis B infection: a review.近年来 Toll 样受体与乙型肝炎病毒感染相互作用的研究进展：综述。
Front Immunol. 2024 Mar 13;15:1363996. doi: 10.3389/fimmu.2024.1363996. eCollection 2024.
7
RDW-SD is Superior to RDW-CV in Reflecting Liver Fibrosis Stage in Patients with Chronic Hepatitis B.红细胞分布宽度标准差在反映慢性乙型肝炎患者肝纤维化分期方面优于红细胞分布宽度变异系数。
Infect Drug Resist. 2023 Oct 27;16:6881-6891. doi: 10.2147/IDR.S427047. eCollection 2023.
8
[Interferon-related gene array in predicting the efficacy of interferon therapy in chronic hepatitis B].[干扰素相关基因阵列在预测慢性乙型肝炎干扰素治疗疗效中的应用]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2023 Feb 25;40(1):79-86. doi: 10.7507/1001-5515.202301014.
9
Resident macrophages of the lung and liver: The guardians of our tissues.肺和肝的固有巨噬细胞：组织的守护者。
Front Immunol. 2022 Nov 30;13:1029085. doi: 10.3389/fimmu.2022.1029085. eCollection 2022.
10
Advances in Immunotherapy for Hepatitis B.乙型肝炎免疫疗法的进展
Pathogens. 2022 Sep 28;11(10):1116. doi: 10.3390/pathogens11101116.
本文引用的文献
1
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.口服 TLR8 激动剂 Selgantolimod 治疗慢性乙型肝炎的安全性、药代动力学和药效学。
Hepatology. 2021 Oct;74(4):1737-1749. doi: 10.1002/hep.31795. Epub 2021 Sep 14.
2
Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells.乙型肝炎病毒对自然杀伤细胞和树突状细胞之间的保护性免疫串扰产生负面影响。
Hepatology. 2021 Aug;74(2):550-565. doi: 10.1002/hep.31725. Epub 2021 May 24.
3
Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes.通过治疗性激活肝细胞中的RIG-I和IRF3信号通路抑制乙型肝炎病毒
iScience. 2021 Jan 4;24(1):101969. doi: 10.1016/j.isci.2020.101969. eCollection 2021 Jan 22.
4
Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation.在肝内初始 CD8+T 细胞中恢复 I 型干扰素信号转导促进功能分化。
JCI Insight. 2021 Feb 8;6(3):145761. doi: 10.1172/jci.insight.145761.
5
Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition.乙型肝炎病毒扰乱细胞代谢组以逃避先天免疫识别。
Nat Commun. 2021 Jan 4;12(1):98. doi: 10.1038/s41467-020-20316-8.
6
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.TLR8 激动剂 GS-9688（Selgantolimod）在慢性乙型肝炎中的治疗潜力：抗病毒和调节介质的重塑。
Hepatology. 2021 Jul;74(1):55-71. doi: 10.1002/hep.31695. Epub 2021 Jun 20.
7
Mucosal-Associated Invariant T Cell Dysregulation Correlates With Conjugated Bilirubin Level in Chronic HBV Infection.黏膜相关恒定T细胞失调与慢性乙型肝炎病毒感染时的结合胆红素水平相关。
Hepatology. 2021 May;73(5):1671-1687. doi: 10.1002/hep.31602. Epub 2021 Mar 26.
8
Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes.Toll 样受体双重作用激动剂是强烈诱导 PBMC 产生细胞因子的物质，可抑制原代人肝细胞中乙型肝炎病毒的产生。
Sci Rep. 2020 Jul 29;10(1):12767. doi: 10.1038/s41598-020-69614-7.
9
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.口服Toll样受体8激动剂塞尔甘托利莫德的安全性、药代动力学和药效学：一项在健康受试者中进行的Ia期研究。
Antivir Ther. 2020;25(3):171-180. doi: 10.3851/IMP3363.
10
Hepatitis B e Antigen Induces NKG2A Natural Killer Cell Dysfunction via Regulatory T Cell-Derived Interleukin 10 in Chronic Hepatitis B Virus Infection.在慢性乙型肝炎病毒感染中，乙肝e抗原通过调节性T细胞衍生的白细胞介素10诱导NKG2A自然杀伤细胞功能障碍。
Front Cell Dev Biol. 2020 Jun 3;8:421. doi: 10.3389/fcell.2020.00421. eCollection 2020.
Zotero 插件